Defining the Science of Multidrug Resistance

Monoclonal Antibodies, Controls and Detection Systems Optimized for the Study of Multidrug Resistance
Call for Papers... 
Instructions for Authors on reverse side.

Clinical Cancer Research

An Official Journal of the American Association for Cancer Research

An exciting new forum for clinical and translational cancer research

EDITOR-IN-CHIEF
John Mendelsohn

ASSOCIATE EDITORS
David S. Alberts
Joseph R. Bertino
Clara D. Bloomfield
George J. Bosl
Patricia Donahoe
Isaiah J. Fidler
Stephen H. Friend
Philip D. Greenberg
Daniel C. Ihde
Marc E. Lippman
Michael T. Lotze
John D. Minna
Richard J. O'Reilly
Ira Pastan
Herbert M. Pinedo
Jerome Ritz
Paul Sondel
Michael B. Sporn
Louise C. Strong
Daniel D. Von Hoff
Ralph R. Weichselbaum

SCOPE

Clinical Cancer Research, a new journal of the American Association for Cancer Research, will publish original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

CALL FOR PAPERS

The Editors welcome the submission of manuscripts for their consideration. Authors should follow the format given in the “Instructions for Authors” on the reverse side. Submit manuscripts to:

John Mendelsohn, M.D., Editor-in-Chief
Clinical Cancer Research
Department of Medicine
Memorial Sloan-Kettering Cancer Center
1275 York Avenue
New York, New York 10021
Telephone 212-639-5878
Fax 212-772-8375

REPRESENTATIVE AREAS OF INTEREST INCLUDE:

Clinical and translational research in:

- Molecular pharmacology and chemotherapy
- Drug sensitivity and resistance
- Tumor immunology and immunotherapy
- Radiobiology and radiation oncology
- Solid tumor oncology
- Hematological malignancies
- Surgical oncology
- Pediatric oncology
- Molecular oncology and cancer genes
- Pathology, markers, and prognostic indicators
- Growth factors, cytokines and signal transduction
- Bone marrow transplantation
- Gene therapy
- Cancer endocrinology
- Cell adhesion, invasion, and metastasis
- Prevention of primary and recurrent cancer
- Differentiation and cell death
- Clinical genetics
- Detection of minimal disease

Clinical Cancer Research will be of interest to professionals in all areas of clinical cancer investigation, including medical and hematological oncology, radiation oncology, pediatric oncology, surgical oncology, pathology, radiology, and clinical genetics.
INSTRUCTIONS FOR AUTHORS

Clinical Cancer Research

SCOPE
Clinical Cancer Research, a new journal of the American Association for Cancer Research, will publish original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

EDITORIAL POLICY
When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.

The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. A copy of the Declaration is available from the American Medical Association, 515 North State Street, Chicago, IL 60610-4320. For animal experimentation reported in the journal, it is expected that investigators will have observed the Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education issued by the New York Academy of Sciences' Ad Hoc Committee on Animal Research, a copy of which is available for $2.00 from the Communications Department, New York Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All human and animal studies must have been approved by the investigator's Institutional Review Board.

REVIEW PROCESS
The review process, expedited by fax transmission and overnight mail service, is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.

MANUSCRIPT SUBMISSION
Send manuscripts to John Mendelsohn, M.D., Editor-in-Chief. Submit four original sets (not photocopies) of figures along with four copies of the manuscript. One set of figures will be returned to the author if the paper is not accepted for publication. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission.

Rapid communication will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for rapid communication should be included in the letter of submission. Minireviews and Forum articles that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.

The letter of submission should suggest the Associate Editor (or Editor-in-Chief) who will serve as primary reviewer of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of up to five potential reviewers who are not current or recent collaborators or advisors in the area under investigation.

FORMAT
Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;
2. A running title of fewer than 50 characters;
3. Abstract, of not more than 250 words, stating briefly the objectives, methods, results, and conclusions of the study;
4. Text arranged in this order: Introduction, Methods, Results, Discussion, Acknowledgments, References;
5. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
6. Tables, on pages separate from the text, with descriptive titles and legends that make the data understandable without reference to the text;
7. Figure legends, on pages separate from the text, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for halftones where applicable;
8. Figures.

REFERENCES
Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission.

SAMPLE REFERENCES:


FIGURES
Provide four original sets of figures (whether line-cut drawings or halftones). Each sorted set should be in a separate labeled envelope, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author's name, figure number, and an arrow indicating top of figure. Letters and numbers on figures should not be larger than 12-point type. All figures will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with greater fidelity. Authors are encouraged to submit color figures. The expense of reproducing color photographs will be charged to the author. Submit color figures on flexible backing.

FOR MORE INFORMATION, CONTACT:
John Mendelsohn, M.D., Editor-in-Chief
Clinical Cancer Research
Department of Medicine, Memorial Sloan-Kettering Cancer Center
1275 York Avenue, New York, New York 10021
Telephone 212-639-5878, Fax 212-772-8375.
AN INTERNATIONAL CANCER RESEARCH SYMPOSIUM
New Approaches in the Therapy Of Breast Cancer

October 20-21, 1994
WASHINGTON, D.C.

Georgetown University Medical Center
Office of Continuing Medical Education
and the
Vincent T. Lombardi Cancer Research Center

CONFERENCE DIRECTORS:
Marc E. Lippman  Robert B. Dickson

15.5 Credit Hours Category 1 PRA AMA
Prizes Will Be Awarded The Top 3 Posters

SCIENTIFIC PROGRAM:

• CELL SURFACE DIRECTED CANCER DRUGS
  Ira Pastan / Bethesda, Maryland
  Nancy Hynes / Basel, Switzerland
  C. Richter King / Gaithersburg, Maryland
  Ruth Lupu / Washington, D.C.
  Karl Erik Hellstrom / Seattle, Washington
  Dennis Slamon / Los Angeles, California

• SIGNAL TRANSDUCTION DIRECTED DRUGS
  Michael Gottesman / Bethesda, Maryland
  Carlos Arteaga / Nashville, Tennessee
  Jackson Gibbs / West Point, Pennsylvania
  Alan Wakeling / Cheshire, England
  David Henderson / Berlin, Germany
  Richard Heyman / San Diego, California

• ANGIOGENESIS AND METASTASIS AS TARGETS OF THERAPY
  Lance Liotta / Bethesda, Maryland
  Judah Folkman / Boston, Massachusetts
  Robert Cohen / San Francisco, California
  Martin Schneider / Berlin, Germany
  Robert Dickson / Washington, D.C.
  Adrian Harris / Oxford, England

• TUMOR VACCINES AND OTHER NEW APPROACHES TO THERAPY
  Michael Friedman / Bethesda, Maryland
  Jeffrey Schlom / Bethesda, Maryland
  William Peters / Durham, North Carolina
  Anton Wellstein / Washington, D.C.
  Michael Hawkins / Washington, D.C.
  Larry Norton / New York, New York

TUITION:
$350 by August 15, 1994 — $400 after August 15, 1994
$150 Registered Nurses; $100 Fellows & Residents

FOR MORE INFORMATION CALL:
Office of Continuing Medical Education
800-382-3613 or 202-687-8735
MODERN DEVELOPMENTS IN CANCER THERAPEUTICS

Joint Conference of the American Association for Cancer Research and the Institute of Biomedical Sciences (Taiwan)

November 7-11, 1994
Academia Sinica, Taipei, Taiwan

ORGANIZING COMMITTEE

AAACR
Yung-Chi Cheng / New Haven Chairperson
Bruce A. Chabner / Bethesda Co-Chairperson
Joseph R. Bertino / New York Co-Chairperson
Edward Bresnick / Hanover Robert L. Capizzi / Philadelphia Paul P. Carbone / Madison Margaret Foti / Philadelphia I. Bernard Weinstein / New York Wendell Wierenga / Ann Arbor

TAIWAN
Cheng-Wen Wu / Taipei Chairperson
Jacqueline J. K. Whang-Peng / Taipei Co-Chairperson
Felicia Y.-H. Wu / Taipei Co-Chairperson
Chungming Chang / Taipei
Kenneth S. S. Chang / Tao-Yuan
Ding-Shinn Chen / Taipei

Kuang Y. Chen / Taipei Chairperson

Drug Discovery
*J. K. Lin / Taipei
*Bruce A. Chabner / Bethesda
Steve R. Roffler / Taipei
Jau Lang Hwang / Taipei
Wendell Wierenga / Ann Arbor
Robert C. Jackson / San Diego
Allen I. Oliff / West Point
Grace W. P. Chao Yeh / Frederick

Experimental Therapeutics
*Robert L. Capizz / Philadelphia
*Wendell Wierenga / Ann Arbor
Felicia Y.-H. Wu / Taipei
Shu-Kuei Liao / Tao-Yuan
Susan B. Horwitz / Bronx
Napoleon Ferrara / S. San Francisco
Rui Han / Beijing
Edward Chu / Bethesda

Tumor Biology
*Ming-Ta Hsu / Taipei
*Edward Bresnick / Hanover
Pei-Jer Chen / Taipei
Cheng-Po Hu / Taipei
The D. Tisty / Chapell Hill
Wen-Hwa Lee / San Antonio
Chawmahn Nag / Madison
Lothar Schweiger / Heidelberg

Gene Therapy and Vaccines
*Joseph R. Bertino / New York
*Ding-Shinn Chen / Taipei
Lih-Hwa Hwang / Taipei
Wen-Kuang Yang / Taipei
Drew M. Pardoll / Baltimore
Alan Gewirtz / Philadelphia
Leaf Huang / Pittsburgh
J. Martin Brown / Stanford

Novel Therapy
*Andrew T. Huang / Taipei
*Paul P. Carbone / Madison
Yao-Chang Chen / Taipei
Kuang Y. Chen / Taipei
Rolf F. Barth / Columbus
Makoto Ogawa / Nagoya
Mark Kaminisky / Ann Arbor
Alice L. Yu / San Diego

Hepatocellular Carcinogenesis:
Treatment and Prevention
* I. Bernard Weinstein / New York
* Juel Low Sung / Taipei
Gh-Ming Lai / Tao-Yuan
Ding-Shinn Chen / Taipei
Zhao-You Tang / Shanghai
Yung-Chi Cheng / New Haven
Brian J. Carr / Pittsburgh

Summary
Bruce A. Chabner / Bethesda

Applicants are encouraged to submit abstracts for poster presentation.

* Indicates Session Chairperson

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)

Institute of Biomedical Sciences
c/o Ms. Iris Li
IBMS, Academia Sinica
Taipei 115, Taiwan, R.O.C.
886-2-789-9007
886-2-782-5573 (FAX)
The U.S. Environmental Protection Agency (EPA) is seeking candidates for the position of Director, Genetic Toxicology Division (GTD), Health Effects Research Laboratory (HERL). This position is located in the Research Triangle Park, NC. This is a permanent, full-time position with a salary range of $68,667 to $89,265 per annum commensurate with qualifications. Additional salary incentives may be available.

HERL has a staff of approximately 230 people and about half hold doctoral-level degrees. The laboratory has a diverse program which includes in vitro, animal and human research designed to address issues related to the health effects of chemical and biological pollutants in air and water.

Presently, the Genetic Toxicology Division is a multidisciplinary carcinogenesis program with an EPA staff of 33 and 32 on-site contractor personnel. The Division recently redirected its research program to fully focus on issues, assumptions, and uncertainties in cancer risk assessment. The refocusing has created a Division that is a focal point for planning, conducting, coordinating, supporting and evaluating research to improve cancer risk assessment. GTD has established a strong research program in environmental carcinogenesis as reflected by its influence in professional organizations, contributions to the regulatory offices of the Agency, impact on Agency guidelines and policy, involvement in international programs, and by the many publications and presentations of its staff.

The incumbent directs and manages the carcinogenesis research program. This program includes both intramural investigations and extramural arrangements with other governmental and nongovernmental organizations. The incumbent provides scientific and managerial leadership of the program, develops the program to meet the evolving needs of EPA, presents the program to both EPA and non-EPA audiences, develops and manages budgets, supervises the staff, directs the progress of the program, and ensures the highest possible scientific quality and productivity.

The preferred candidate for this position would possess the following qualifications:

1. Advanced degree in a biological, biochemical, toxicological, or medical discipline. Within any of these areas he/she must have at least six years of professional research experience. Applicable graduate course work may be substituted for a portion of the preferred experience.

2. Experience as a supervisor of a scientific/professional staff.

3. Recognized scientific expertise as evidenced by multiple peer-reviewed publications, presentations at national and international meetings/panels, and involvement with international organizations.

4. Proven ability to provide leadership in directing the development and progress of a creative and effective multidisciplinary carcinogenesis research program.

5. U.S. citizenship is required.

Forward curriculum vitae and names of three references prior to August 1, 1994 to: Dr. Harold Zenick, c/o Dorothy Carr, HRMD (MD-29), U.S. Environmental Protection Agency, Research Triangle Park, NC 27711.
The U.S. Environmental Protection Agency (EPA) is seeking candidates for the position of Director, Genetic Toxicology Division (GTD), Health Effects Research Laboratory (HERL). This position is located in the Research Triangle Park, NC. This is a permanent, full-time position with a salary range of $68,667 to $89,265 per annum commensurate with qualifications. Additional salary incentives may be available.

HERL has a staff of approximately 230 people and about half hold doctoral-level degrees. The laboratory has a diverse program which includes in vitro, animal and human research designed to address issues related to the health effects of chemical and biological pollutants in air and water.

Presently, the Genetic Toxicology Division is a multidisciplinary carcinogenesis program with an EPA staff of 33 and 32 on-site contractor personnel. The Division recently redirected its research program to fully focus on issues, assumptions, and uncertainties in cancer risk assessment. The refocusing has created a Division that is a focal point for planning, conducting, coordinating, supporting and evaluating research to improve cancer risk assessment. GTD has established a strong research program in environmental carcinogenesis as reflected by its influence in professional organizations, contributions to the regulatory offices of the Agency, impact on Agency guidelines and policy, involvement in international programs, and by the many publications and presentations of its staff.

The incumbent directs and manages the carcinogenesis research program. This program includes both intramural investigations and extramural arrangements with other governmental and nongovernmental organizations. The incumbent provides scientific and managerial leadership of the program, develops the program to meet the evolving needs of EPA, presents the program to both EPA and non-EPA audiences, develops and manages budgets, supervises the staff, directs the progress of the program, and ensures the highest possible scientific quality and productivity.

The preferred candidate for this position would possess the following qualifications:

1. Advanced degree in a biological, biochemical, toxicological, or medical discipline. Within any of these areas he/she must have at least six years of professional research experience. Applicable graduate course work may be substituted for a portion of the preferred experience.
2. Experience as a supervisor of a scientific/professional staff.
3. Recognized scientific expertise as evidenced by multiple peer-reviewed publications, presentations at national and international meetings/panels, and involvement with international organizations.
4. Proven ability to provide leadership in directing the development and progress of a creative and effective multidisciplinary carcinogenesis research program.
5. U.S. citizenship is required.

Forward curriculum vitae and names of three references prior to August 1, 1994 to: Dr. Harold Zenick, c/o Dorothy Carr, HRMD (MD-29), U.S. Environmental Protection Agency, Research Triangle Park, NC 27711.

---

14TH INTERNATIONAL SYMPOSIUM ON CANCER
SAPPORO CANCER SEMINAR
"GENETIC POLYMORPHISM AND CANCER SUSCEPTIBILITY"

July 5-8, 1994
Century Royal Hotel, Sapporo, Japan

This will be the first international Symposium in Japan to devote itself to a discussion of the problems of the genetic polymorphism of carcinogen-metabolizing enzymes and susceptibility to cancer. The organizers hope by this means to set in motion in Japan the study of genetic susceptibility of human cancer.

Guest Speakers

F. J. Gonzalez (Bethesda)  N. E. Caporaso (Bethesda)
F. P. GueiGerich (Nashville)  J. B. Groopman (Baltimore)
F. F. Kadlubar (Jefferson)  J. Doehmer (Munich)
F. Oesch (Mainz)  H. Esumi (Tokyo)
H. Bartsch (Heidelberg)  K. Kawajiri (Saitama)
Y. Fuji-Kuriyama (Sendai)  Y. Hashimoto (Sendai)
Y. Yamazoe (Tokyo)  M. Degawa (Sendai)
R. Kato (Tokyo)  S. Kawara (Sendai)
N. Harada (Toyoakae)  M. Watanabe (Sendai)
T. Yokoi (Sapporo)  T. Watabe (Tokyo)
T. Kimataki (Sapporo)  T. Sugimura (Tokyo)
R. A. Branch (Pittsburgh)

Registration Fee: 20,000 yen (to be paid at the Symposium)

For Registration and Information, contact:

Dr. Minio Watanabe
Dept. of Molecular Genetics
Institute of Development, Aging, and Cancer
Tohoku University
Seiryo-machi 4-1
Aoba-ku, Sendai 980
JAPAN

Telephone: 81-22-273-9504 or 81-22-274-1111 (ext. 3439)
Fax: 81-22-272-4927
Pictured on this issue's cover are Silvio Garattini, M.D. (left), Professor of pharmacology and chemotherapy, founder and director of the Mario Negri Institute for Pharmacological Research (Milan); Carlo La Vecchia (right), Professor of epidemiology; and Eva Negri (center), an expert in epidemiological methodology. The buildings of the Negri Institute are featured in the bottom illustration.

The Mario Negri Institute was established as a nonprofit foundation in 1963 by Mario Negri, a far-sighted philanthropist who designated Silvio Garattini, then a young professor at the University of Milan, to establish a research group to study human diseases, with particular emphasis on the mechanisms of action of drugs.

Now, 30 years later, the center in Milan has been expanded to include two other institutes in Italy, one in S. Maria Imbaro, Chieti, in the south of Italy, and one in Ranica, near Bergamo, where a Clinical Research Center for Orphans is being completed. The initial staff of 22 has grown to over 800, at least half at the doctoral level. About 2000 young people have received various kinds of training, including over 400 foreign scientists from 50 countries. More than 4500 scientific papers have been written and published by the Institute's researchers in international journals; these have covered experimental and clinical studies in cancer, mental illness, cardiovascular and renal diseases, and neuroendocrine and aging-related diseases.

The Mario Negri Institute has contributed much to cancer research and its scientists are internationally known. They include Dr. Alberto Mantovani, in the area of immunology; Dr. Maurizio D’Incalci, in antitumoral chemotherapy; Dr. Raffaella Giavazzi, in cancer metastasis; Drs. Maria Benedetta Donati and Andreina Poggi, in the relationship between blood coagulation and cancer progression; Dr. Silvia Marsoni, in clinical trials on ovarian tumors; and Dr. Alessandro Liberati, in clarifying the quality of cancer care and establishing guidelines for the treatment of tumors in women.

To increase understanding of the mechanisms bearing on cancer causation, extensive research has been done in epidemiology, including systematic analyses of cancer trends in Europe and worldwide, with the goals of identifying and quantifying major differences in cancer patients in various areas of the world; examining separate and combined effects of alcohol and tobacco on carcinogenesis; identifying an independent role of alcohol in the risk of cancers of the upper digestive and respiratory tract, and its strong synergism with tobacco; gaining a deeper understanding of dietary correlates of cancer risk in the population of the Mediterranean area, where a diet rich in fresh fruit and vegetables, and hence in selected micronutrients, provides substantial protection against the risk of several neoplasms; understanding occupational carcinogenesis, with specific reference to bladder cancer following extensive exposure to aromatic amines in humans; quantifying protection against cervical cancer by screening at various ages and different time schedules; and developing the field of pharmacoepidemiology and cancer risk, including acquiring reliable data on the impact of oral contraceptives and H2 receptor antagonists on subsequent cancer risk.

Professor Garattini received his M.D. from the University of Turin in 1954. He has been director of the Mario Negri Institute since its inception in 1963 and over the years has overseen its enormous growth into its three main units in Milan, Chieti, and Bergamo. He is a member of the Italian National Research Council and the National Health Council and a founding member of the European Organisation for Research on the Treatment of Cancer. His scientific work, particularly in relation to central nervous system diseases and cancer, has been acknowledged worldwide. He has been awarded the French Legion d’Honneur and honorary degrees from universities in Europe and the United States and has published over 400 papers, books, and book chapters in pharmacology, pharmacokinetics, cancer chemotherapy, cancer metastasis, and psychopharmacology.

Dr. La Vecchia is Head of the Laboratory of Epidemiology and Associate Professor of Epidemiology at Milan University Institute of Biometrics and Medical Statistics. He received his M.D. from the University of Milan in 1979 and his Master of Science in Clinical Medicine (Epidemiology) from Oxford, United Kingdom, in 1983. From 1982 to 1983 he was Research Fellow at the Department of Public Health, Oxford, and from 1987 to 1992, Associate Professor of Epidemiology at the University of Lausanne, Switzerland. In 1991 he received the European Visiting Professorship to the Royal Society of Medicine, London, and in 1993 the Glaxo Prize for Medical Publications. He is a registered journalist in Milan, a member of several WHO and UICC Committees, Editor of the European Journal of Public Health, and a member of the editorial board of several journals. Dr. La Vecchia’s bibliography lists over 500 titles, mainly in the epidemiology and etiology of cancer and other chronic diseases.

Dr. Negri is Head of the Unit of Epidemiological Methodology. She received her Sc.D. in Mathematics in 1985 from the University of Milan and did postdoctorate studies in Medical Statistics in 1988. In 1988–1989 she won a European Economic Community Scholarship for postgraduate training in epidemiology at Cambridge, United Kingdom. Dr. Negri has published over 200 papers, largely in epidemiology and biostatistics, together with Dr. La Vecchia and other colleagues.

We are indebted to all featured, especially Dr. Garattini, for information and photographs.

John H. Weisburger